146 related articles for article (PubMed ID: 32108909)
1. Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Almholt K; Wang J; Pass J; Røder G; Padkjær SB; Hebsgaard JB; Xia W; Yang L; Forsell J; Breinholt VM; Thygesen P; Agersø H; Loftager M; Usher PA
J Mol Med (Berl); 2020 Apr; 98(4):585-593. PubMed ID: 32108909
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Almholt K; Hebsgaard JB; Nansen A; Andersson C; Pass J; Rønø B; Thygesen P; Pelzer H; Loftager M; Lund IK; Høyer-Hansen G; Frisch T; Jensen CH; Otte KS; Søe NH; Bartels EM; Andersen M; Bliddal H; Usher PA
J Immunol; 2018 Feb; 200(3):957-965. PubMed ID: 29282305
[TBL] [Abstract][Full Text] [Related]
3. A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential.
Liu X; Li L; Wang Q; Jiang F; Zhang P; Guo F; Liu H; Huang J
Front Immunol; 2021; 12():816646. PubMed ID: 35126375
[TBL] [Abstract][Full Text] [Related]
4. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
[TBL] [Abstract][Full Text] [Related]
5. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
8. The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Buckley BJ; Ali U; Kelso MJ; Ranson M
Curr Drug Targets; 2019; 20(9):970-981. PubMed ID: 30516104
[TBL] [Abstract][Full Text] [Related]
9. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
10. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera.
Matsuno H; Yudoh K; Nakazawa F; Sawai T; Uzuki M; Nishioka K; Yonehara S; Nakayama J; Ohtsuki M; Kimura T
J Rheumatol; 2002 Aug; 29(8):1609-14. PubMed ID: 12180717
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.
Ellis V; Danø K
J Biol Chem; 1993 Mar; 268(7):4806-13. PubMed ID: 8444857
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterisation of CR6086, a potent prostaglandin E
Caselli G; Bonazzi A; Lanza M; Ferrari F; Maggioni D; Ferioli C; Giambelli R; Comi E; Zerbi S; Perrella M; Letari O; Di Luccio E; Colovic M; Persiani S; Zanelli T; Mennuni L; Piepoli T; Rovati LC
Arthritis Res Ther; 2018 Mar; 20(1):39. PubMed ID: 29490676
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys.
Saito M; Yoshigae Y; Nakayama J; Ogawa Y; Ohtsuki M; Kurihara A; Ikeda T
Life Sci; 2007 May; 80(22):2005-14. PubMed ID: 17477938
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.
Hosoya T; Iwai H; Yamaguchi Y; Kawahata K; Miyasaka N; Kohsaka H
Ann Rheum Dis; 2016 Jan; 75(1):253-9. PubMed ID: 25165034
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody.
Wang W; Leu J; Watson R; Xu Z; Zhou H
AAPS J; 2018 Apr; 20(3):63. PubMed ID: 29667047
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator.
Nolli ML; Corti A; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787
[TBL] [Abstract][Full Text] [Related]
19. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.
Cole P; Rabasseda X
Drugs Today (Barc); 2004 Apr; 40(4):281-324. PubMed ID: 15190385
[TBL] [Abstract][Full Text] [Related]
20. A novel mode of intervention with serine protease activity: targeting zymogen activation.
Blouse GE; Bøtkjaer KA; Deryugina E; Byszuk AA; Jensen JM; Mortensen KK; Quigley JP; Andreasen PA
J Biol Chem; 2009 Feb; 284(7):4647-57. PubMed ID: 19047064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
